Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical Trial.

ABSTRACT:

Importance

Lupus nephritis is typically treated with intravenous cyclophosphamide, which is associated with serious adverse effects. Oral mizoribine may be an alternative for induction therapy of lupus nephritis. However, large-scale, long-term, randomized clinical studies of mizoribine are lacking.

Objective

To assess the efficacy and safety of oral mizoribine vs intravenous cyclophosphamide as induction therapy for Chinese patients with lupus nephritis.

Design, setting, and participants

This prospective, multicenter, parallel-group, open-label, phase 3 randomized clinical trial recruited patients with class III, III+V, IV, IV+V, or V lupus nephritis aged 18 to 70 years from 40 centers in China. Inclusion criteria included 24-hour urinary protein level of 1.0 g or hi

SUBMITTER: Dong Z 

PROVIDER: S-EPMC11909609 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature